In a meta-analysis of 15 trials including over 20,000 patients conducted by Cardoso et al., SGLT-2 inhibitors were shown to significantly reduce all-cause mortality and cardiovascular mortality in patients with HF stratified by age, sex, race, renal function, diabetic status, the functional class of HF and ejection fraction [10]. Here, SLC5A2 is linked to hydrops fetalis.